Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Chief Scientific Officer | June 24, 2019 | June 26, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 24, 2019 · Filed June 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 · Expires 2029-06-23 | Direct | 71,025 |
Reported balance
After 2019-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-24 · Grant · Acquired 71,025 · Balance 71,025 F1: Vests in eight nearly equal quarterly installments over two years. |
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 2,000 |
Reported balance
Holding disclosure · report date 2019-06-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in eight nearly equal quarterly installments over two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2019 Filed Jun 26, 2019 20:54 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 71,025 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000066 · primary_doc.xml · derivative · entry 2 Verdoorn Todd A. · CIK 0001759883 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,025 Underlying: Common Shares · 71,025 shares Expires 2029-06-23 F1 · derivative.exercise_date: Vests in eight nearly equal quarterly installments over two years. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:42 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseVoting Common Shares, no par value per share | 1,000 | $4.00 | $4,000.00 |
DisclosureSEC source: 0001235802-18-000184 · primary_doc.xml · nonDerivative · entry 1 Verdoorn Todd A. · CIK 0001759883 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.